RIPK2 and breast neoplasm: Elevated RIPK2 expression in breast tumors correlates with poor prognosis and a higher risk of recurrence, while RIPK2 knockdown inhibits NF-κB signaling, reduces anti-apoptotic proteins, and increases drug sensitivity.